Cargando…
Applications of coxsackievirus A21 in oncology
The clinical management of cancer continues to be dominated by macroscopic surgical resection, radiotherapy, and cytotoxic drugs. The major challenge facing oncology is to achieve more selective, less toxic and effective methods of targeting disseminated tumors, a challenge oncolytic virotherapy may...
Autores principales: | Bradley, Stephen, Jakes, Adam D, Harrington, Kevin, Pandha, Hardev, Melcher, Alan, Errington-Mais, Fiona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918364/ https://www.ncbi.nlm.nih.gov/pubmed/27512662 http://dx.doi.org/10.2147/OV.S56322 |
Ejemplares similares
-
Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015) -
Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008) -
Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015) -
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
por: Müller, Louise M. E., et al.
Publicado: (2019) -
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)